Evidence-based peptide information for research and educational purposes only.
Navaro HealthNavaro Health
Energy & Endurance

AOD-9604

← Back to Library
Protocol not independently verified FDA safety flag Metabolic Aesthetics
Educational reference only. Read the full disclaimer. The protocols below are not automatically an FDA-approved or clinically verified regimen unless explicitly marked as label-verified or human-trial protocol above.

Compound Profile

AOD-9604 is reviewed here for cellular energy, stamina, and recovery.

Research Summary

Evidence Strength Very limited
Primary Evidence

Safety notices, literature searches, limited protocol data

Research Focus

Cellular energy, Stamina, Recovery

Mechanism

Target context: HGH Lipolytic Fragment (177-191)

Long-Term Data

Limited, unclear, or affected by safety flags.

Current Consensus

Claims need extra caution because evidence is thin or safety flags apply.

Route(s) Subcutaneous
Typical dose 300 mcg
Dosing window Morning Fasted
Receptor / target HGH Lipolytic Fragment (177-191)
Properties Half-life: ~3 hours
Pre-mixed No

Protocols

Standard Protocol

TimeframeDoseNotes
Weeks 1-4300 mcg 1x Daily FastedAM upon waking preferred, do not eat 2-4 hrs post pinning.
Weeks 5-12500 mcg 1x Daily FastedAM upon waking preferred, do not eat 2-4 hrs post pinning.

Protocol example for research-context comparison; verify against the evidence status and listed medical sources.

Alternative Titration 1

TimeframeDoseNotes
Weeks 1-3300 mcg 1x Daily FastedAM upon waking preferred, do not eat 2-4 hrs post pinning.

Alternative research-context example; not an approved-label regimen unless marked above.

Alternative Titration 2: Weight Loss Protocol

TimeframeDoseNotes
Weeks 1-3250mcg 2x Daily FastedAM upon waking and PM 1hr post meal, do not eat 2-4 hrs post pinning.

Alternative research-context example; not an approved-label regimen unless marked above.

Protocol logic check

Protocol context: Energy protocols are usually about mitochondrial or metabolic signaling. The logic is timing around meals/training, avoiding late-day stimulation, and watching sleep, glucose, blood pressure, and overtraining signals. Entry context: target (HGH Lipolytic Fragment (177-191)); route Subcutaneous; timing Morning Fasted. Unapproved or unverified dosing examples are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. AOD-9604 is often sold with spot-fat-loss language, but the dosing logic should stay systemic and evidence-cautious. Local injection claims do not prove local fat loss, and appetite, diet adherence, and total energy balance still decide visible change.

Medical literature and study context

Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.

Evidence positionFDA safety-risk context or unapproved compounded-use warning is attached to this entry; no FDA-approved human label was identified for this compound/page context.
Where studiedStudied in metabolism, mitochondrial function, substrate use, exercise physiology, glucose handling, or endurance models.
Source systems checkedFDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records
Target and route contextTarget/receptor: HGH Lipolytic Fragment (177-191). Route(s): Subcutaneous. Dosing window on page: Morning Fasted.
Protocol anchorNo source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
Main evidence limitKey limitation: FDA safety-risk context plus missing approved-label dosing; published mechanisms do not remove compounding, purity, sterility, or human-safety uncertainty.

Source-linked findings

  • AOD-9604 is a modified growth-hormone fragment studied for lipolysis and metabolic endpoints; the literature includes preclinical work and limited human obesity research.
  • It should not be treated as equivalent to approved growth-hormone therapy, and FDA compounding concerns reduce confidence in non-label preparations.
  • FDA lists AOD-9604 among withdrawn nominated bulk substances with potential significant safety risks and limited safety information.

Protocol and study notes

  • No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
  • On-page protocol examples summarized for comparison: Standard Protocol: Weeks 1-4, 300 mcg 1x Daily Fasted; Alternative Titration 1: Weeks 1-3, 300 mcg 1x Daily Fasted.
  • Key limitation: FDA safety-risk context plus missing approved-label dosing; published mechanisms do not remove compounding, purity, sterility, or human-safety uncertainty.
  • Monitor sleep, heart rate, blood pressure, glucose response, training load, appetite, and stimulant overlap.

Selected medical sources

Independent evidence

Independent safety notes: FDA lists AOD-9604 among withdrawn nominated bulk substances with potential significant safety risks and limited safety information.

Regulatory status: unapproved or compounded peptide with FDA safety risk flag

Storage

No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.

  • Active cancer or history of growth hormone-sensitive tumors: although AOD-9604 does not significantly elevate IGF-1, any compound acting on GH-adjacent pathways warrants caution in oncology contexts.
  • Concurrent use with Adipotide: both compounds target adipose tissue through distinct destructive or disruptive mechanisms; combined use creates unpredictable and potentially dangerous systemic fat cell stress.
  • Concurrent use with AOD-CJC-IPA blend: results in double-dosing of AOD-9604 within the same protocol.
  • Pregnancy: safety not established; potential fetal risk.
  • Breastfeeding: safety not established.
  • Known hypersensitivity or anaphylaxis to AOD-9604 or formulation excipients.
  • Severe hepatic impairment: limited metabolic clearance data.
  • Severe renal impairment: limited clearance data; dehydration risk.
  • Endocrine disorders involving active GH excess (e.g., acromegaly): additive lipolytic GH pathway stimulation.
  • Diabetes mellitus requiring tight glycemic management: while AOD-9604 does not directly alter glucose, rapid systemic lipolysis releases free fatty acids that may transiently affect insulin sensitivity in brittle diabetics.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.

  • Injection site reactions: redness, swelling, and irritation at the administration site; reported in approximately 12.8% of subjects in Phase 2 data.
  • Nausea: reported in approximately 8.4% of subjects; typically mild and transient.
  • Headache: reported in approximately 6.7% of subjects; often dose-related and more common at the 500mcg dose.
  • Fatigue or lethargy during the adaptation period: reported in approximately 5.3% of subjects.
  • Dizziness: reported in approximately 3.8% of subjects.
  • Flushing: transient warmth or redness, particularly following injection; attributed to beta-3 adrenergic activation.
  • Transient changes in appetite: increased or decreased hunger during early protocol stages; inconsistent across subjects.
  • Gelation-related injection issues: failure to reconstitute with acetic acid/bacteriostatic water blend results in a gelled, ineffective solution that causes unnecessary injection site irritation.
  • Blunted efficacy from feeding: eating within 2 hours post-injection significantly reduces lipolytic effect; not a side effect per se but a primary protocol compliance risk.
  • Allergic reactions: rare; localized rash or itching at injection site.

Compatibility

The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

CJC-1295 (No DAC / Modified GRF 1-29)IpamorelinTirzepatideRetatrutide

Reported contraindicated combinations:

Adipotide (FTPP)aod-cjc-ipa-blend

Sources